Related Experiment Videos
The interleukin-8 receptor: a potential target for antipsoriatic therapy?
L Kemény1, A S Kenderessy, E Olasz
1Department of Dermatology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
European Journal of Pharmacology
|June 13, 1994
Summary
Antipsoriatic drugs like cyclosporine decrease interleukin-8 (IL-8) binding to keratinocytes and block IL-8-induced HLA-DR expression. This suggests the IL-8 receptor is a molecular target for psoriasis treatment.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Interleukin-8 (IL-8) is implicated in psoriasis pathogenesis.
- Increased IL-8 receptor expression is noted in psoriatic skin and leukocytes.
Purpose of the Study:
- To investigate if the IL-8 receptor is a molecular target for antipsoriatic drugs.
- To evaluate the effect of common antipsoriatic compounds on IL-8 binding and function in keratinocytes.
Main Methods:
- Cultured human keratinocytes and granulocytes were used.
- Interleukin-8 (IL-8) binding assays were performed.
- The expression of human leukocyte antigen-DR (HLA-DR) was measured after IL-8 stimulation and drug treatment.
Main Results:
- Cyclosporine, calcitriol, calcipotriol, and dithranol reduced IL-8 binding to keratinocytes in a dose-dependent manner.
- IL-8 binding to granulocytes remained unaffected by these drugs.
- Antipsoriatic drug treatment significantly inhibited IL-8-induced HLA-DR expression on keratinocytes.
Conclusions:
- Antipsoriatic drugs inhibit the keratinocyte IL-8 receptor and its function.
- This inhibition may contribute to the therapeutic effects of these drugs in psoriasis.
- The IL-8 receptor represents a potential molecular target for novel antipsoriatic therapies.